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Abstract
Alzheimer’s disease (AD) and related dementias are a major public health challenge and present a therapeutic imperative for
which we need additional insight into molecular pathogenesis. We performed a genome-wide association study and
analysis of known genetic risk loci for AD dementia using neuropathologic data from 4,914 brain autopsies.
Neuropathologic data were used to define clinico-pathologic AD dementia or controls, assess core neuropathologic
features of AD (neuritic plaques, NPs; neurofibrillary tangles, NFTs), and evaluate commonly co-morbid neuropathologic
changes: cerebral amyloid angiopathy (CAA), Lewy body disease (LBD), hippocampal sclerosis of the elderly (HS), and
vascular brain injury (VBI). Genome-wide significance was observed for clinico-pathologic AD dementia, NPs, NFTs, CAA, and
LBD with a number of variants in and around the apolipoprotein E gene (APOE). GalNAc transferase 7 (GALNT7), ATP-Binding
Cassette, Sub-Family G (WHITE), Member 1 (ABCG1), and an intergenic region on chromosome 9 were associated with NP
score; and Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Beta Member 2 (KCNMB2) was strongly
associated with HS. Twelve of the 21 non-APOE genetic risk loci for clinically-defined AD dementia were confirmed in our
clinico-pathologic sample: CR1, BIN1, CLU, MS4A6A, PICALM, ABCA7, CD33, PTK2B, SORL1, MEF2C, ZCWPW1, and CASS4 with 9
of these 12 loci showing larger odds ratio in the clinico-pathologic sample. Correlation of effect sizes for risk of AD dementia
with effect size for NFTs or NPs showed positive correlation, while those for risk of VBI showed a moderate negative
correlation. The other co-morbid neuropathologic features showed only nominal association with the known AD loci. Our
results discovered new genetic associations with specific neuropathologic features and aligned known genetic risk for AD
dementia with specific neuropathologic changes in the largest brain autopsy study of AD and related dementias.
Citation: Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, et al. (2014) Genome-Wide Association Meta-analysis of Neuropathologic Features of
Alzheimer’s Disease and Related Dementias. PLoS Genet 10(9): e1004606. doi:10.1371/journal.pgen.1004606
Editor: Greg Gibson, Georgia Institute of Technology, United States of America
Received February 3, 2014; Accepted July 14, 2014; Published September 4, 2014
Copyright:  2014 Beecham et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PLOS Genetics | www.plosgenetics.org 1 September 2014 | Volume 10 | Issue 9 | e1004606
Funding: The National Institutes of Health, National Institute on Aging (NIH-NIA) supported this work through the following grants: ADGC, U01 AG032984, RC2
AG036528; NACC, U01 AG016976; NCRAD, U24 AG021886; NIA LOAD, U24 AG026395, U24 AG026390; Banner Sun Health Research Institute P30 AG019610; Boston
University, P30 AG013846, U01 AG10483, R01 CA129769, R01 MH080295, R01 AG017173, R01 AG025259, R01AG33193; Columbia University, P50 AG008702, R37
AG015473; Duke University, P30 AG028377, AG05128; Emory University, AG025688; Group Health Research Institute, UO1 AG06781, UO1 HG004610; Indiana
University, P30 AG10133; Johns Hopkins University, P50 AG005146, R01 AG020688; Massachusetts General Hospital, P50 AG005134; Mayo Clinic, P50 AG016574; Mount
Sinai School of Medicine, P50 AG005138, P01 AG002219; New York University, P30 AG08051, MO1RR00096, UL1 RR029893, 5R01AG012101, 5R01AG022374,
5R01AG013616, 1RC2AG036502, 1R01AG035137; Northwestern University, P30 AG013854; Oregon Health & Science University, P30 AG008017, R01 AG026916; Rush
University, P30 AG010161, R01 AG019085, R01 AG15819, R01 AG17917, R01 AG30146; TGen, R01 NS059873; University of Alabama at Birmingham, P50 AG016582,
UL1RR02777; University of Arizona, R01 AG031581; University of California, Davis, P30 AG010129; University of California, Irvine, P50 AG016573, P50, P50 AG016575,
P50 AG016576, P50 AG016577; University of California, Los Angeles, P50 AG016570; University of California, San Diego, P50 AG005131; University of California, San
Francisco, P50 AG023501, P01 AG019724; University of Kentucky, P30 AG028383, AG05144; University of Michigan, P50 AG008671; University of Pennsylvania, P30
AG010124; University of Pittsburgh, P50 AG005133, AG030653; University of Southern California, P50 AG005142; University of Texas Southwestern, P30 AG012300;
University of Miami, R01 AG027944, AG010491, AG027944, AG021547, AG019757; University of Washington, P50 AG005136; Vanderbilt University, R01 AG019085; and
Washington University, P50 AG005681, P01 AG03991. The Kathleen Price Bryan Brain Bank at Duke University Medical Center is funded by NINDS grant # NS39764,
NIMH MH60451 and by Glaxo Smith Kline. Genotyping of the TGEN2 cohort was supported by Kronos Science. The TGen series was also funded by NIA grant
AG041232, the Banner Alzheimer’s Foundation, The Johnnie B. Byrd Sr. Alzheimer’s Institute, the Medical Research Council, and the state of Arizona and also
includes samples from the following sites: Newcastle Brain Tissue Resource (funding via the Medical Research Council, local NHS trusts and Newcastle
University), MRC London Brain Bank for Neurodegenerative Diseases (funding via the Medical Research Council), South West Dementia Brain Bank (funding via
numerous sources including the Higher Education Funding Council for England (HEFCE), Alzheimer’s Research Trust (ART), BRACE as well as North Bristol NHS
Trust Research and Innovation Department and DeNDRoN), The Netherlands Brain Bank (funding via numerous sources including Stichting MS Research, Brain
Net Europe, Hersenstichting Nederland Breinbrekend Werk, International Parkinson Fonds, Internationale Stiching Alzheimer Onderzoek), Institut de
Neuropatologia, Servei Anatomia Patologica, Universitat de Barcelona. ADNI Funding for ADNI is through the Northern California Institute for Research and
Education by grants from Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation,
Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F.
Hoffman-La Roche, Schering-Plough, Synarc, Inc., Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, the Dana Foundation, and by the National
Institute of Biomedical Imaging and Bioengineering and NIA grants U01 AG024904, RC2 AG036535, K01 AG030514. Support was also from the Alzheimer’s
Association (LAF, IIRG-08-89720; MAP-V, IIRG-05-14147) and the US Department of Veterans Affairs Administration, Office of Research and Development,
Biomedical Laboratory Research Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: tmontine@uw.edu
" Membership of the Alzheimer’s Disease Genetics Consortium (ADGC) is provided in Text S1.
Introduction
Studies of brain aging with brain autopsy endpoint have
repeatedly demonstrated that dementia in older individuals most
often derives from three common diseases: Alzheimer’s disease
(AD), vascular brain injury (VBI) especially small vessel disease,
and Lewy body (LB) disease (LBD) [1]. Importantly, while each of
these diseases exclusively can cause dementia, they commonly co-
exist in older patients with dementia [2]. These same brain
autopsy studies also commonly observed pathologic changes of
AD, LBD, and/or VBI in older individuals carefully demonstrated
to be cognitively normal proximate to death. Indeed, it was these
observations from cognitively intact ‘‘controls’’ that first led to the
hypothesis of cognitive reserve, the idea of excess functional
capacity that can mask clinical expression of disease. Biomarker
and molecular neuroimaging studies also have observed abnormal
changes in cognitively normal individuals that typically occur in
patients with dementia, and have demonstrated with longitudinal
observation that some of these changes are pathologic [3]. Thus,
dementia in older individuals is a syndrome that derives most
commonly from the idiosyncratic convergence of three chronic
disease processes, AD, VBI, and/or LBD, that each appear to
have prevalent latency prior to clinical expression.
The suffering to patients and loved ones and cost to health care
systems from the global burden of dementia are staggering, and
projected to increase markedly in the coming 20 years [4]. While
interventions exist to mitigate some types of VBI, the major unmet
medical needs are disease-modifying therapies for AD and LBD.
Many efforts are underway to achieve this therapeutic imperative,
although none yet has met with reproducible success in clinical
trials. One response to these setbacks is to revise the approach to
existing therapeutic targets, such as using existing experimental
interventions in earlier stages of disease or in selected subgroups.
Another approach is to increase the repertoire of therapeutic
targets by expanding our knowledge of the molecular drivers of
disease; this rationale animates the several recent genome-wide
association studies (GWAS) for AD [5–11].
Given the pathologic complexity of AD and related dementias,
and the prevalence of latent disease, we hypothesized that direct
analysis of neuropathologic features might align known genetic risk
loci with specific diseases processes as well as identify novel genetic
variants associated with specific neuropathologic features. To test
these hypotheses the Alzheimer’s Disease Genetics Consortium
(ADGC) assembled a set of 4,914 samples with genome-wide
genotyping data and neuropathologic data, and performed
genome-wide association tests of AD and related diseases. We
performed both genome wide association and analyses focused on
known AD dementia genetic risk loci while using three approaches
to the neuropathologic data: a clinico-pathologic definition of AD
dementia or controls, focus on the core neuropathologic features of
AD, i.e., neurofibrillary tangles (NFTs) and neuritic plaques (NPs),
in cases and controls combined, and inclusion of commonly co-
morbid neuropathologic features observed in older individuals
with dementia, i.e., cerebral amyloid angiopathy (CAA), LBD,
hippocampal sclerosis in the elderly (HS), and VBI.
Results
Genome-wide association
First we performed a GWAS of clinico-pathologic AD
dementia, that is, cases with clinical dementia confirmed to have
moderate to high levels of core AD pathologic changes and
controls without dementia and no or low levels of core AD
pathologic changes (Table 1). Results and Quantile-Quantile
plots are detailed in the supporting material (Tables S1, S2;
Figures S1, S2). A number of variants in and around the
apolipoprotein E gene (APOE) achieved genome-wide significance
(rs6857, p-value = 2610262). One additional variant in the PHD
Finger Protein 21B gene (PHF21B) achieved genome-wide
significance (chr22:45354131, p-value = 1.961028). However,
GWAS Meta-analysis of Pathologic Features of AD and Related Dementias
PLOS Genetics | www.plosgenetics.org 2 September 2014 | Volume 10 | Issue 9 | e1004606
the variant was only imputed in one dataset (albeit the largest set,
ADC), had a low minor allele frequency (MAF) ( = 0.017), had a
modest imputation info score ( = 0.428), and was not well-
supported by association at other variants in the region (Figure
S3). These are typically the signs of a false positive, but we do note
that a recent meta-analysis of primarily clinic-based samples by the
International Genomics of Alzheimer’s Project (IGAP) [11] found
nominal association at this locus (p-value = 0.00659), with the
same direction of effect as we report. There is however some
sample overlap between this and the Lambert et al study.
We also performed a GWAS of core AD pathologic changes; we
performed two ordinal analyses for NFT and an ‘‘any vs. none’’
NP analysis (presence of NPs as one category and absence of NPs
as another; see Methods). We found variants in the APOE region
to be highly associated with both NPs (p-value,10246 any-none;
p-value,10226 ordinal) and NFTs (p-value,10246 ordinal with
seven categories; p-value,10243 ordinal with four categories)
(Tables S3, S4, S5, S6, Figures S4, S5, S6, S7). Three
additional loci were significantly associated with NPs in the ‘‘any
vs. none’’ analysis: GalNAc transferase 7 (GALNT7; minimum p-
value = 6.061029; Figure 1), ATP-Binding Cassette, Sub-Family
G (WHITE), Member 1 (ABCG1; minimum p-value = 8.061029;
Figure 2), and an intergenic region on chromosome 9 (minimum
p-value = 4.361028; Figure 3). Each of these three loci were
tested in multiple datasets, and there was no evidence of
heterogeneity of effect size (heterogeneity p-value.0.5 for each;
Figures S8, S9, S10). These three additional loci were not
significantly associated in the recent IGAP analysis (p-value.
0.05). There were no additional genome-wide significant loci with
the NP ordinal analysis or the NFT analyses (Tables S3, S4,
S5, S6).
Our last GWAS was of co-morbid neuropathologic features.
APOE showed significant genome wide association for both CAA
(minimum p-value = 2.8610223), and LBD (minimum p-value,
1.1610212) but was not strongly associated with VBI or with HS
(Tables S7, S8, S9, S10, S11, S12, S13; Figures S11, S12,
S13, S14, S15, S16, S17). HS had significant genome-wide
association with an intergenic region on chromosome 18
(minimum p-value = 4.661028; Figure 4) and strong association
at the Potassium Large Conductance Calcium-Activated Channel,
Subfamily M, Beta Member 2 gene (KCNMB2) on chromosome 3
(minimum p-value = 7.161028; Figure 5). The chromosome 18
locus was only tested in one dataset – the largest set, ADC, while
the KCNMB2 locus was tested in multiple datasets and showed no
evidence of heterogeneity of effect size (heterogeneity p-value.0.5;
Figure S18). The chromosome 18 locus did show suggestive
association with AD risk in the IGAP analysis (p-value = 0.0611)
with an effect size in the same direction reported here. No other
significant genome-wide association was discovered for CAA,
LBD, or VBI (Table 2).
Analysis of known AD dementia genetic risk loci
The ADGC, together with international collaborators under the
banner of IGAP (International Genomics of Alzheimer’s Project)
has to-date identified 21 common genetic loci associated with AD
dementia using primarily clinically ascertained datasets
[7,8,10,11], in addition to confirming the APOE locus [12].
One of our goals in the study presented here was to test the
hypothesis that pathologic confirmation of dementia or control
status might reduce phenotypic heterogeneity and thereby
enhance known genetic associations with AD dementia. We used
two sets that met our clinico-pathologic criteria for case or control
(Table 1): the ‘‘primary’’ dataset had 3887 cases and 1027
controls which allowed some incomplete documentation of
pathologic features, and the ‘‘complete’’ dataset which had 3044
case and 658 controls with more stringent documentation
standards. The primary clinico-pathologic analysis confirmed (p-
value,0.05) association with 12 of the 21 previously identified
Table 1. Case-control criteria.
Clinicala Pathologic Phenotype Decision
NIA/Reaganb NP scorec NFT Braak staged
Dementia Group intermediate or high likelihood — — Neuropathologic AD
— moderate or frequent III–VI
Not Demented Group low likelihood — — Neuropathologic Control
— none or sparse 0, I, or II
— none III or IV
Neuropathologically-confirmed AD and control criteria. Abbreviations: NP: neuritic plaque; NFT: neurofibrillary tangles. AD: Alzheimer’s disease.
aDementia Group met DSM-IV criteria or had a clinical dementia rating greater than zero. Not Demented Group did not meet DSM-IV criteria for dementia, had no mild
cognitive impairment and—when available—a clinical dementia rating of zero.
bHyman and Trojanowski, 1997 [23].
cMirra et al., 1993 [21].
dBraak and Braak, 1991 [22].
doi:10.1371/journal.pgen.1004606.t001
Author Summary
Alzheimer’s disease (AD) and related dementias are a
major public health challenge and present a therapeutic
imperative for which we need additional insight into
molecular pathogenesis. We performed a genome-wide
association study (GWAS), as well as an analysis of known
genetic risk loci for AD dementia, using data from 4,914
brain autopsies. Genome-wide significance was observed
for 7 genes and pathologic features of AD and related
diseases. Twelve of the 22 genetic risk loci for clinically-
defined AD dementia were confirmed in our pathologic
sample. Correlation of effect sizes for risk of AD dementia
with effect size for hallmark pathologic features of AD
were strongly positive and linear. Our study discovered
new genetic associations with specific pathologic features
and aligned known genetic risk for AD dementia with
specific pathologic changes in a large brain autopsy study
of AD and related dementias.
GWAS Meta-analysis of Pathologic Features of AD and Related Dementias
PLOS Genetics | www.plosgenetics.org 3 September 2014 | Volume 10 | Issue 9 | e1004606
[11] non-APOE loci: CR1, BIN1, CLU, MS4A6A, PICALM,
ABCA7, CD33, PTK2B, SORL1, MEF2C, ZCWPW1, and
CASS4; 9 of these also were confirmed in the ‘‘complete’’ analysis
(Table 3). All loci but one (CELF1) had a consistent direction of
effect with the odds ratio (OR) previously reported (Figure 6).
Nine of the twelve loci confirmed in the clinico-pathologic datasets
had stronger OR with AD dementia than was observed previously.
This is more than would be expected at random (paired t-test p-
value = 0.00029 among confirmed loci; p-value = 0.033 among all
21 non-APOE loci); OR for CLU and PTK2B were essentially
unchanged from the previous report, and the OR for CR1 was
reduced in our study. These results are consistent with less
heterogeneity in our clinico-pathologic sample compared to
studies with purely clinical ascertainment schemes. Rare variation
in the recently discovered TREM2 and PLD3 genes [13,14] was
not imputed on our reference panel and as such was not assessed
in this study. Some nominal association (p-value,0.05) was noted
in these genes (e.g., with PLD3 and the MTS phenotype, marker
19-40373284 had a p-value = 0.006118; with TREM2 and the
four category Braak phenotype, marker rs17328707 had a p-
value = 0.001132, etc). However, given that over 240 markers
were tested in each gene, even these minimum p-values would not
withstand a gene-based multiple testing correction.
Next we tested the hypothesis that the 21 common AD loci are
varyingly associated with the core AD neuropathologic features
among all subjects, combining cases and controls (n = 4,914). The
effect sizes for 12 of the 21 loci (11 of the 12 confirmed loci) were
significantly associated with one or both of the core neuropath-
ologic features of AD with a consistent direction of effect (Table
S14). Though CR1 is associated with clinico-pathologic AD, we
do not confirm the previously reported associations with NPs and
CAA [15]; we do confirm the previous associations with CD2AP
and ABCA7 and NPs [15]. To gain additional insight into the
potential molecular drivers of specific neuropathologic features, we
compared the effect sizes for risk of AD dementia (function) with
the effect sizes for the two core AD neuropathologic features
(structure) across these 21 loci in all subjects. Effect size estimates
for both NFTs and NPs were strongly positively correlated to the
previously reported effect sizes (p-value,1026 for the NFT ordinal
traits; p-value,1026 for the NP ordinal analysis; p-value,1024
for NP ‘‘any vs. none’’ analysis (Figure 7; Figure S19).
The co-incident neuropathologic features showed only nominal
association with the known AD loci (Table S15). LBD (n= 3526)
was nominally associated with MEF2C with effect sizes similar to
both NFTs and NPs. LBD was also nominally associated with
SORL1, with an effect size direction opposite that previously
reported for AD dementia. HS (n= 2866) was nominally
associated with PTK2B; VBI (n = 2940) showed nominal associ-
ation at NME8; CAA (n= 2807) showed no association with any
of the previously reported loci. We next compared the co-morbid
neuropathologic features effect size estimates to the known AD risk
effects (Figure 7). While the core AD feature effect sizes showed
strong, positive correlations with the previously reported effect
sizes, the picture at co-morbid features was more complicated.
Figure 1. Regional association plot for GALNT7 and the neuritic plaque (any vs. none) analysis. The purple dot indicates the most
associated SNP in the region. The x-axis is basepair position, and y-axis is the 2log(p-value), base 10.
doi:10.1371/journal.pgen.1004606.g001
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LBD effect sizes showed weak moderate positive correlations with
the previously reported effect sizes (Figure S20; slope p-
value = 0.035), while VBI showed a moderate negative correlation
with the previously reported AD dementia effect sizes (Figure
S21; slope p-value = 0.0292). To test if these correlations had to do
with the study ascertainment scheme, we repeated the analysis but
using cases only; in the case-only set LBD effect sizes were no
longer correlated with the previously reported effect sizes (p-
value = 0.86), while the correlation of the VBI effect sizes with
those previously reported was stronger (p-value = 4.2261024)
(Figures S20, S21).
Finally, we compared NP effect sizes against the effect sizes for
NFTs and CAA at each of these loci; we observed a strong,
positive, and linear association between effect sizes of NPs and
NFTs, but no correlation between NPs and CAA (Figure 7).
Discussion
Cognitive impairment among older individuals is a complex
convergent trait that often occurs with mixed pathology: AD,
LBD, and VBI, which each have prevalent prodromal and latent
stages in addition to full clinical expression as dementia. Indeed,
approximately 95% of subjects without dementia in this age group
have some pathologic evidence of at least one of these three
diseases. These facts as first discovered in neuropathologic studies
of brain aging and subsequently validated in part by neuroimaging
and biomarker studies present serious challenges to diagnose
accurately and comprehensively the diseases that cause an
individual’s dementia based exclusively on clinical data, and
clearly demonstrate that age-matched control populations are
variably, and potentially extensively, ‘‘contaminated’’ with latent
disease. Virtually all previous GWAS of AD have been based on
cases and controls defined exclusively by clinical criteria. To
address this limitation, we undertook a GWAS of dementia that
focused on neuropathologic data (i) to test the hypothesis that
clinico-pathologic characterization of cases and controls could be
used to strengthen previous genetic associations with AD made by
clinical criteria, (ii) to test the hypothesis that genetic associations
for AD dementia will selectively align with specific neuropatho-
logic features, and (iii) to discover new genetic associations with
neuropathologic features of AD and related dementias.
Although we assembled a large brain autopsy cohort, it is still a
relatively modest number of samples for GWAS compared to the
larger IGAP GWAS where subjects were primarily clinically
diagnosed cases and controls. The reduction in statistical power
due to a smaller sample must be balanced against improved
phenotypic homogeneity. With this balance in mind, our study
confirmed 12 of the 21 previously reported loci as significantly
associated with AD dementia. Our association with clinico-
pathologic AD dementia was strengthened for 9 of these 12 loci
(ABCA7, BIN1, CASS4, CD33, MEF2C, MS4A6A, PICALM,
SORL1, and ZCWPW1), essentially unchanged for CLU and
PYK2B, and diminished for CR1 to unity with increasingly
stringent pathologic criteria. CR1 also is the only locus that we
confirmed as associated with AD dementia that was not
significantly associated with a specific neuropathologic feature.
Figure 2. Regional association plot for ABCG1 and the neuritic plaque (any vs. none) analysis. The purple dot indicates the most
associated SNP in the region. The x-axis is basepair position, and y-axis is the 2log(p-value), base 10.
doi:10.1371/journal.pgen.1004606.g002
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One possible explanation is that previous associations of CR1 with
AD dementia may be related more to clinical expression of disease
rather than to the accumulation of NPs and NFTs; it is of note
though that CR1 has been associated with NPs and CAA
previously [15]. The same may be true for the other 9 loci that
were not confirmed in our clinico-pathologic case-control analysis;
however, lack of confirmation also may be the result of limitations
of smaller sample size outweighing the potential advantages of
reduced phenotypic heterogeneity or perhaps even spurious
associations in previous studies.
Clinical expression of dementia encompasses at least several
processes that include disease mechanisms that produce stress and
injury, response to injury, physiologic compensation, and cognitive
reserve. Our second major goal was to determine the alignment
between AD dementia genetic risk loci and specific neuropatho-
logic features that are core to (NPs and NFTs) or co-morbid with
(LBD, VBI, HS, CAA) AD in an attempt to clarify the relevant
molecular mechanisms that underlie these characteristic lesions
that are related to injury and response to injury. Association tests
for NFTs and NPs were significant for five of the previously
reported loci that were validated in our clinico-pathologic GWAS
(ABCA7, BIN1, CASS4, MEF2C, and PICALM); NFTs were
specifically associated with CLU, SORL1, and ZCWPW1, and
NPs were specifically associated with MS4A6A and CD33. In all
instances the effect sizes for NPs or NFTs were in the same
direction as the previously reported effects for AD dementia.
Effects sizes for LBD were increased with SORL1 and decreased
with MEF2C, and HS was associated with PTK2B; no significant
association was observed between previously reported AD
dementia loci and VBI or CAA. Association of LBD with SORL1
locus is novel and, interestingly, the effect size was in the direction
opposite to its association with NFTs. The SORL1 locus has not
been identified in previous studies of Parkinson’s disease (PD),
another LBD, but these were investigations of PD defined by its
movement disorder rather than LBD in the context of AD
dementia as we have done here; this unexpected association will
require replication and further investigation. We analyzed NPs
and NFTs as binary (any vs. none) and finer graded (ordinal)
phenotypes; stronger associations were observed with binary
analyses perhaps because of variation in assigning histopathologic
stages to these characteristic AD lesions.
We observed a linear correlation between the previously
reported AD dementia effect sizes and the effect sizes for NPs
and NFTs determined in our cohort whether we included all 21
IGAP loci or limited our analysis to the 12 loci confirmed in our
clinico-pathologic investigation. We do not think this is a foregone
conclusion. Indeed, the literature is replete with commentary that
one or both of the core AD lesions are a product of brain aging
rather than AD. Our results strongly support the view that the
molecular drivers underlying the accumulation of NPs and NFTs
in brain are largely shared with the molecular drivers of severely
impaired cognitive function. Interestingly, there was not a
significant correlation with CAA, suggesting that this other form
of amyloidosis has a different genetic risk profile than NP
Figure 3. Regional association plot for the chromosome 9:129,280,000–129,380,000 region and the neuritic plaque (any vs. none)
analysis. The purple dot indicates the most associated SNP in the region. The x-axis is basepair position, and y-axis is the 2log(p-value), base 10.
doi:10.1371/journal.pgen.1004606.g003
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accumulation. Using the same approach, correlation of effect sizes
for IGAP loci with effect sizes for LBD was at best weakly positive,
and for VBI was negative. This last observation was unexpected
and, if validated, might indicate that the genetic risk architecture
for AD and VBI are inversely related, an intriguing possibility that
stimulates speculation over why this may be. It also suggests a
possible approach to genetic stratification of risk for two of the
most common causes of cognitive impairment and dementia in
older individuals.
Our third goal was genome-wide discovery of associations with
the six neuropathologic features to gain additional insights into the
molecular drivers of these characteristic lesions. As expected, there
was a very strong association of the APOE locus with our clinico-
pathologically defined AD dementia. We observed a strong
association between the APOE locus and NFTs, NPs, CAA, and
LBD, but not with HS or VBI. While the association of APOE
with both core features and a secondary neuropathologic feature
of AD is expected from ascertainment bias, the association with
LBD may not be so simple. Indeed, an association between APOE
and Dementia with Lewy bodies (DLB) has been varyingly
supported or refuted in several smaller studies that did not include
pathologic evaluation to exclude contribution from unknown and
likely varying amounts of AD. However, in a recent large study of
DLB and PD dementia that included pathologic evaluation, we
demonstrated that inheritance of APOE e4 allele is a significant
risk factor for DLB even in the absence of AD [16]. In addition,
our GWAS showed a genome-wide significant association between
NPs and ABCG1, a locus previously implicated in AD [17]. The
association of NPs with GALNT7 is novel and potentially
reinforces existing genetic associations with other genes that
encode for members of this family of transferases. Indeed,
alteration in the O-glycosylation pattern of amyloid beta peptides
and NPs has been reported in AD [18–20]. Finally, we made a
novel association of HS with a variant of KCMNB2, which
encodes a subunit of a Ca++-gated K+ channel that is key to
neuronal excitability and is highly expressed by hippocampal
pyramidal neurons in sector CA1. Although this discovery requires
validation, it may have significance beyond AD dementia since HS
also occurs frequently in some forms of fronto-temporal dementia.
While additional replication datasets are ideal for these novel loci,
we do note that the meta-analysis approach here is a type of
replication, and that all of the novel variants with support from
multiple datasets had no signs of heterogeneity of effect size.
In summary, this genetic association study of autopsy brain
enhanced some and diminished other known genetic risk loci for
AD dementia, highlighted a subset of the loci previously associated
with AD dementia as potential molecular drivers of specific
neuropathologic features of AD, and discovered new genetic loci
associated with specific neuropathologic features. These novel
results provide new insights into new candidate therapeutic targets
for AD and related dementias that will require validation and
functional investigation.
Figure 4. Regional association plot for the chromosome 18:6,420,000–6,520,000 region and the hippocampal sclerosis (any vs.
none) analysis. The purple dot indicates the most associated SNP in the region. The x-axis is basepair position and y-axis is the 2log(p-value), base
10.
doi:10.1371/journal.pgen.1004606.g004
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Methods
Sample selection
Samples were contributed by the National Institute on Aging (NIA)
Alzheimer’s Disease Centers (ADCs) and ADGC-collaborating
studies. The ADC dataset includes samples ascertained and evaluated
by the Clinical and Neuropathology Cores of the 29 NIA-funded
ADCs. The National Alzheimer’s Coordinating Center (NACC)
organizes a collection of phenotype data from the ADCs, organizes its
database, coordinates implementation of definitions of AD cases and
controls, and oversees collection and distribution of samples.
The ADGC collaborating studies include the Adult Changes in
Thought study (ACT; Eric B. Larson, PI), the Mayo Clinic
Alzheimer’s Disease Research Center (MAYO; Steven G.
Younkin, PI), the University of Miami Brain Endowment Bank
(MBB; Deborah Mash, PI), the National Institute on Aging Late-
Onset Alzheimer’s Disease Family Study (NIA-LOAD; Richard
Mayeux, PI), the Oregon Health & Science University Alzheimer’s
Disease Center (OHSU; Patricia Kramer, PI), the Religious
Orders Study and Memory and Aging Project (ROSMAP; David
Bennett, PI), the Translational Genomics Research Institute
(TGEN; Eric Reiman, PI), the University of Pittsburgh Alzhei-
mer’s Disease Research Center (UP; Kamboh, PI), the University
of Miami Hussman Institute for Human Genomics (UM; Pericak-
Vance, PI), the Vanderbilt University Center for Human Genetics
Research (VU; Jonathan Haines, PI), and the Mount Sinai School
of Medicine (MSSM; Joseph Buxbaum PI) (see Table S16 for
details; descriptive statistics found in Table S17).
All samples had thorough neuropathologic examination ac-
cording to consensus criteria that existed at the time that our study
was initiated. Prior to analysis, neuropathologic data were
reviewed and harmonized by a single neuropathologist (TJM) to
ensure consistency across assessment sites.
Neuropathology methods and eligibility criteria
Samples were evaluated at each site. Assessment of NPs and
NFTs followed the protocols of CERAD [21], and Braak and
Braak [22], respectively, at all sites. Criteria for assessment of co-
morbid features were reviewed with each site and only those
using comparable methods, i.e., immunohistochemistry for
alpha-synuclein to detect LBs, and similar sampling protocols
were included in our analyses. For inclusion as a case, the subject
must have been diagnosed with dementia (DSM-IV criteria or
clinical dementia rating greater than zero) and the subject’s
autopsy must have either NIA/Reagan classification of interme-
diate or high likelihood of AD [23], or have an NP score of
moderate/frequent and NFT Braak stage of III–VI. For
inclusion as a neuropathologically-confirmed control, each
subject must not have had a clinical diagnosis of dementia or
MCI within two years of death (does not meet DSM-IV criteria
for dementia, no mild cognitive impairment, and—when
available—clinical dementia rating of zero), no diagnosis of
other neurologic disease by clinical or neuropathologic evalua-
tion, and must have had low likelihood of AD by NIA/Reagan
criteria, or none/sparse NPs and NFT Braak stage of 0, I, or II.
If no NPs were identified, then an NFT Braak stage III or IV was
Figure 5. Regional association plot for KCNMB2 and the hippocampal sclerosis (any vs. none) analysis. The purple dot indicates the most
associated SNP in the region. The x-axis is basepair position, and y-axis is the 2log(p-value), base 10.
doi:10.1371/journal.pgen.1004606.g005
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accepted in the control group (Table 2). In total 5,981 samples
were eligible for inclusion in our analyses.
Core AD neuropathologic phenotypes
The core AD neuropathologic phenotypes analyzed were NFTs
and NPs. NFTs were analyzed in two well-established ordinal
rankings (seven Braak stages: none, I, II, III, IV, V, and VI; and
four Braak groups: none, transentorhinal, limbic, isocortical). NPs
were analyzed with one ordinal ranking (four CERAD scores:
none, sparse, moderate, frequent) and a presence vs. absence (any
NPs vs. no NPs) analysis. Sample sizes by cohort are described in
Table S18.
Co-morbid neuropathologic phenotypes
There were four co-morbid neuropathologic phenotypes
analyzed: LBD, VBI, HS, CAA. LBD was analyzed with two
ordinal rankings (five categories: none, brainstem-predominant,
limbic, neocortical, and other regions or not specified; three
categories: none, brainstem-predominant, and all other regions or
not specified) and a presence vs. absence (any LBD vs. no LBD)
analysis. VBI was analyzed in an ordinal ranking (three categories:
none, any microinfarcts, any lacunar or territorial infarcts) and in
a presence vs. absence (any VBI vs. no VBI) analysis. HS and CAA
were both analyzed using presence vs. absence analyses. Sample
sizes by cohort are described in Table S18.
Clinico-pathologic AD dementia phenotypes
Additionally, we performed a case/control analysis of clinico-
pathologic AD dementia. That is, cases had clinical dementia with
core AD neuropathologic changes, and controls were not clinically
demented and had none or minimal AD neuropathologic changes.
Two ‘‘case-control’’ datasets were considered. For the ‘‘primary’’
dataset, all cases and controls were included, regardless of the
documentation from the primary neuropathologist. The secondary
dataset (‘‘complete’’ dataset) required more thorough documenta-
tion of the neuropathologic assessment, including documentation
of the NIA/Reagan assessment or complete documentation of
both the NFT Braak stage and the NP score. Sample sizes by
cohort are described in Table S18.
Genotyping and quality control (QC)
Genotyping for the ADC samples was performed at the
Children’s Hospital of Pennsylvania on the Illumina 660k
beadchip. Genotyping of ADGC collaborating centers was
performed on a variety of genotyping platforms and is described
in Naj et al 2011 [8]. QC and statistical analyses are summarized
in Figure S22. Preliminary QC includes checks for sample
relatedness, sex inconsistency, sample missingness, and principal
components analysis of genotype data to confirm the sample’s
race, and is described by Naj and colleagues [8,24,25]. The top
principal components were further used as covariates in the
association analysis (see below).
Genotype imputation and final QC
To infer genotypes at loci not on the genotyping chips, we used
IMPUTE v2 software [26] in all datasets, using the 1,000
Genomes Project data as a reference [27]. Imputation and
imputation QC were performed independently across the different
datasets, but with all using the December 2010 release of the 1,000
Genomes Data. For inclusion in the statistical analysis, variants
must have high quality imputation (IMPUTE info score greater
than 0.40 and a dosage variance greater than 0.0198 (the
estimated variance of a 1% MAF SNP). We also required an
MAF.1% (estimated based on dosage data) as the study is not
well-powered for low frequency variants.
Statistical analysis
See Supporting Material for an overview of analyses. For binary
traits, logistic regression was used, with principal components 1–3
included as covariates to account for population substructure; the
Figure 6. Barplot of OR for known AD risk loci (all 21 loci). Red indicates the estimated OR previously reported through the IGAP consortium
[11], green indicates the estimated OR from our primary clinico-neuropathologic case-control analysis, and blue indicates the estimated OR from a
more restrictive analysis that required complete documentation of all relevant neuropathologic phenotypes.
doi:10.1371/journal.pgen.1004606.g006
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analysis was performed using PLINK genetic analysis software
[24]. For ordinal traits, we used polytomous logistic regression
with principal components 1–3 included as covariates to account
for population substructure; the analysis was performed with the
polr function (part of the MASS package [28]) in the R statistical
analysis software (http://www.r-project.org/). Polytomous logistic
regression is an extension of logistic regression that allows for
analysis of categorical data. As these data were either binary or
ordinal, we used the proportional odds assumption to obtain a
single effect-size estimate for each SNP for each of the ordinal
traits.
Association analysis was performed within each cohort sepa-
rately, and results were meta-analyzed across cohorts. Because
some datasets had small sample size or had incomplete phenotyp-
ing, we only considered a set for a particular analysis if that set had
at least two categories with at least five individuals in each
category. That is, for binary traits the set had to include both cases
and controls. For categorical traits, the set had to have at least two
categories on which analysis could be performed. The sets
included (and categories used) in the particular analyses are
described in Table S8. After the within dataset association
analysis, we used METAL [29], to meta-analyze result across
Figure 7. Correlations of OR for known AD risk loci and the neuropathology phenotypes. Bottom left indicates the magnitude, direction,
and confidence interval of the correlation. Top right shows plots of the data points against each other. The diagonal box indicates the phenotypes;
off-diagonal boxes indicate the correlations of the OR for the corresponding phenotypes.
doi:10.1371/journal.pgen.1004606.g007
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datasets, weighting each effect size by the inverse of the variance
estimated from the logistic or polytomous logistic regression
analyses, and to calculate heterogeneity statistics for each meta-
analysis. QQ-plots for each trait are included (see supporting
material).
To compare effect sizes at previously identified AD loci, we
performed linear regression and correlation analyses of the
estimated effect sizes (and OR) at the loci. Regression was
performed using the R statistical software with the ‘‘glm’’ function
[30], and the ‘‘corrgrams’’ package [31]. As linear regression in
small datasets can be heavily influenced by outliers, we removed
the outliers (plus or minus 3 standard deviations from the mean)
prior to regression and correlation analyses.
Supporting Information
Figure S1 QQ plot for primary endpoint. QQ Plot for the
primary clinico-neuropathologic case-control analysis. The anal-
ysis was not inflated for false positives (GIF= 0.972).
(TIF)
Figure S2 QQ plot for complete endpoint. QQ plot for the
‘‘complete’’ clinico-neuropathologic case-control analysis. The
analysis was not inflated for false positives (GIF= 0.949).
(TIF)
Figure S3 Regional association plot of the PHF21B locus. The
purple dot indicates the most associated SNP in the region. The x-
axis is basepair position, and y-axis is the 2log(p-value), base 10.
(TIF)
Figure S4 QQ plot for NFT Braak (four category) endpoint.
QQ plot for the NFT Braak (four category ordinal) analysis. The
analysis was not inflated for false positives (GIF= 0.975).
(TIF)
Figure S5 QQ plot for NFT Braak (seven category) endpoint.
QQ plot for the NFT Braak (seven category ordinal) analysis. The
analysis was not inflated for false positives (GIF= 0.987).
(TIF)
Figure S6 QQ plot for Neuritic plaque (any-none) endpoint.
QQ plot for the Neuritic plaque (case-control) analysis. The
analysis was not inflated for false positives (GIF= 0.962).
(TIF)
Figure S7 QQ plot for Neuritic plaque (ordinal) endpoint. QQ
plot for the Neuritic plaque (ordinal) analysis. The analysis was not
inflated for false positives (GIF=0.977).
(TIF)
Figure S8 Forest plot for GALNT7 locus and Neuritic
plaque(rs62341097). Forest plot of the rs62341097 variant, in
terms of the odds ratio.
(TIF)
Figure S9 Forest Plot for ABCG1 locus and Neuritic plaque
(chr21:43,678,066). Forest plot of the associated chr21 locus, in
terms of the odds ratio.
(TIF)
Figure S10 Forest Plot for chr9 locus and Neuritic plaque
(chr9:129,356,304). Forest plot of the associated chr9 locus, in
terms of the odds ratio.
(TIF)
Figure S11 QQ plot for Lewy Body (any-none) endpoint. QQ
plot for the Lewy Body (case-control) analysis. The analysis was
not inflated for false positives (GIF= 0.954).
(TIF)
Figure S12 QQ plot for Lewy Body (three category) endpoint.
QQ plot for the Lewy Body (three category ordinal) analysis. The
analysis was not inflated for false positives (GIF= 0.956).
(TIF)
Figure S13 QQ plot for Lewy Body (five category) endpoint.
QQ plot for the Lewy Body(five category ordinal) analysis. The
analysis was not inflated for false positives (GIF= 0.963).
(TIF)
Figure S14 QQ plot for Amyloid Angiopathy endpoint. QQ
plot for the Amyloid Angiopathy (case-control) analysis. The
analysis was not inflated for false positives (GIF= 0.956).
(TIF)
Figure S15 QQ plot for Hippocampal Sclerosis endpoint. QQ
plot for the Hippocampal Sclerosis (case-control) analysis. The
analysis was not inflated for false positives (GIF= 0.968).
(TIF)
Figure S16 QQ plot for vascular brain injury (any-none)
endpoint. QQ plot for the VBI (case-control) analysis. The
analysis was not inflated for false positives (GIF= 0.967).
(TIF)
Figure S17 QQ plot for vascular brain injury (ordinal) endpoint.
QQ plot for the VBI (ordinal) analysis. The analysis was not
inflated for false positives (GIF= 0.967).
(TIF)
Figure S18 Forest plot of the KCNMB2 locus and hippocampal
sclerosis (rs9637454). Forest plot of the associated rs9637454 locus,
in terms of the odds ratio.
(TIF)
Figure S19 Correlation of IGAP reported effect sizes and core
AD neuropathology effect sizes. Regression of effect size estimates
(betas) against those previously reported for the core neuropathol-
ogy features.
(TIF)
Figure S20 Correlation of IGAP reported effect sizes and Lewy
Body neuropathology effect sizes. Regression of effect size
estimates (betas) against those previously reported for Lewy Body
features.
(TIF)
Figure S21 Correlation of IGAP reported effect sizes and
vascular brain injury effect sizes. Regression of effect size estimates
(betas) against those previously reported for VBI features.
(TIF)
Figure S22 Analysis workflow. Overview of the analysis process.
This approach was taken for each phenotype independently of the
other phenotypes.
(TIF)
Table S1 Top association signals from the primary case-control
phenotype. Chr: chromosome number; EA: effect allele; RA:
reference allele; Freq: frequency of effect allele; min/maxFreq: the
minimum and maximum within cohort allele frequency; Effect:
allele effect, in terms of the beta coefficient.
(PDF)
Table S2 Top association signals from the complete case-control
phenotype. Chr: chromosome number; EA: effect allele; RA:
reference allele; Freq: frequency of effect allele; min/maxFreq: the
minimum and maximum within cohort allele frequency; Effect:
allele effect, in terms of the beta coefficient.
(PDF)
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Table S3 Top association signals from the neurofibrillary tangle
(NFT) Braak ordinal I phenotype. Chr: chromosome number; EA:
effect allele; RA: reference allele; Freq: frequency of effect allele;
min/maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S4 Top association signals from the neurofibrillary tangle
(NFT) Braak ordinal II phenotype. Chr: chromosome number;
EA: effect allele; RA: reference allele; Freq: frequency of effect
allele; min/maxFreq: the minimum and maximum within cohort
allele frequency; Effect: allele effect, in terms of the beta
coefficient.
(PDF)
Table S5 Top association signals from the neuritic plaque
ordinal phenotype. Chr: chromosome number; EA: effect allele;
RA: reference allele; Freq: frequency of effect allele; min/
maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S6 Top association signals from the neuritic plaque case-
control phenotype. Chr: chromosome number; EA: effect allele;
RA: reference allele; Freq: frequency of effect allele; min/
maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S7 Top association signals from the Lewy body disease
(LBD) ordinal I phenotype. Chr: chromosome number; EA: effect
allele; RA: reference allele; Freq: frequency of effect allele; min/
maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S8 Top association signals from the Lewy body disease
(LBD) case-control phenotype. Chr: chromosome number; EA:
effect allele; RA: reference allele; Freq: frequency of effect allele;
min/maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S9 Top association signals from the Lewy body disease
(LBD) ordinal II phenotype. Chr: chromosome number; EA: effect
allele; RA: reference allele; Freq: frequency of effect allele; min/
maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S10 Top association signals from the vascular brain injury
(VBI) case-control phenotype. Chr: chromosome number; EA:
effect allele; RA: reference allele; Freq: frequency of effect allele;
min/maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S11 Top association signals from the vascular brain injury
(VBI) ordinal phenotype. Chr: chromosome number; EA: effect
allele; RA: reference allele; Freq: frequency of effect allele; min/
maxFreq: the minimum and maximum within cohort allele
frequency; Effect: allele effect, in terms of the beta coefficient.
(PDF)
Table S12 Top association signals from the hippocampal
sclerosis (HS) case-control phenotype. Chr: chromosome number;
EA: effect allele; RA: reference allele; Freq: frequency of effect
allele; min/maxFreq: the minimum and maximum within cohort
allele frequency; Effect: allele effect, in terms of the beta
coefficient.
(PDF)
Table S13 Top association signals from the cerebral amyloid
angiopathy (CAA) case-control phenotype. Chr: chromosome
number; EA: effect allele; RA: reference allele; Freq: frequency of
effect allele; min/maxFreq: the minimum and maximum within
cohort allele frequency; Effect: allele effect, in terms of the beta
coefficient.
(PDF)
Table S14 Association of common AD risk variants with core
AD neuropathologic features. Bold text indicates p-values meeting
an alpha= 0.05 threshold, uncorrected for multiple testing.
(PDF)
Table S15 Association of common AD risk variants with
coincident neuropathologic features. Bold text indicates p-values
meeting an alpha= 0.05 threshold; uncorrected for multiple
testing.
(PDF)
Table S16 Cohort contact information. ACT: Adult Changes in
Thought Study; ADC: Alzheimer’s Disease Center; MAYO:
Mayo Clinic Alzheimer’s Disease Research Center; MBB:
University of Miami Brain Endowment Bank; NIA-LOAD:
National Institute on Aging Late–Onset Alzheimer’s Disease
Family Study; OHSU: Oregon Health & Science University
Alzheimer’s Disease Center; ROSMAP: Religious Orders Study
and Memory and Aging Project; TGEN: Translational Genomics
Research Institute; UM/VU/MSSM: University of Miami Huss-
man Institute for Human Genomics/Vanderbilt University Center
for Human Genetics Research/Mount Sinai School of Medicine;
UP: University of Pittsburgh Alzheimer’s Disease Research
Center; ADGC: Alzheimer’s Disease Genetics Consortium;
dbGAP: database of genotypes and phenotypes; eMERGE:
electronic medical records and genomics; NACC: National
Alzheimer’s Coordinating Center; NCRAD: National Cell
Repository for Alzheimer’s Disease.
(PDF)
Table S17 Descriptive statistics of cohorts. AAO: age at onset;
AAD: age at death; AAE: age at exam; SD: standard deviation.
APOE: relative frequency of APOE genotypes where * represents
E2 or E3. Cohorts: ACT: Adult Changes in Thought Study; ADC:
Alzheimer’s Disease Center; TGEN: Translational Genomics
Research Institute; LOAD: National Institute on Aging Late-
Onset Alzheimer’s Disease Family Study; MAYO: Mayo Clinic
Alzheimer’s Disease Research Center; ROSMAP: Religious
Orders Study and Memory and Aging Project; UPITT: University
of Pittsburgh Alzheimer’s Disease Research Center; UM/MASH:
University of Miami Brain Endowment Bank; OHSU: Oregon
Health & Science University Alzheimer’s Disease Center; UM/
VU/MSSM: University of Miami Hussman Institute for Human
Genomics/Vanderbilt University Center for Human Genetics
Research/Mount Sinai School of Medicine.
(PDF)
Table S18 Sample size and cohort inclusion by phenotype. A
missing point (‘‘.’’) indicates the category had fewer than 5
observations and was not included in the analysis. A cohort must
have 5 observations in two or more categories to be included in a
particular analysis. Ordinal traits were coded in the order listed
here. ACT: Adult Changes in Thought Study; ADC: Alzheimer’s
Disease Center; OHSU: Oregon Health & Science University
Alzheimer’s Disease Center; MAYO: Mayo Clinic Alzheimer’s
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Disease Research Center; MBB: University of Miami Brain
Endowment Bank; NIA-LOAD: National Institute on Aging Late-
Onset Alzheimer’s Disease Family Study; ROSMAP: Religious
Orders Study and Memory and Aging Project; TGEN: Transla-
tional Genomics Research Institute; UM/VU/MSSM: University
of Miami Hussman Institute for Human Genomics/Vanderbilt
University Center for Human Genetics Research/Mount Sinai
School of Medicine; UP: University of Pittsburgh Alzheimer’s
Disease Research Center.
(PDF)
Text S1 Additional Alzheimer’s Disease Genetics Consortium
(ADGC) members and affiliations.
(DOCX)
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